Clinical Trials
124 trialsA Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
BeOne Medicines
A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors
Cogent Biosciences, Inc.
A Phase 1 Study of the Safety and Tolerability of CTX-10726
Compass Therapeutics
Study of PF-07265807 in Participants With Metastatic Solid Tumors.
Pfizer
A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations
Atavistik Bio, Inc
OMNIRAY
Eli Lilly and Company
A First-in-Human Study of HH160 in Patients With Advanced Solid Tumors
Huahui Health
A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors
IDEAYA Biosciences
A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors
Context Therapeutics Inc.
A Study of LY4175408 in Participants With Advanced Cancer
Eli Lilly and Company
A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies
SEED Therapeutics, Inc.
Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
AstraZeneca
A Study to Test How Well Different Doses of BI 3820768 Are Tolerated by People With Advanced Cancer (Solid Tumours)
Boehringer Ingelheim
A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors
Alterome Therapeutics, Inc.
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors
GlaxoSmithKline
Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-304 in Adults With Advanced HER2-Expressing Solid Tumors
Myeloid Therapeutics
Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors
Revolution Medicines, Inc.
A Study of PHST001 in Advanced Solid Tumors
Pheast Therapeutics
RAD301
Radiopharm Theranostics, Ltd
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
NiKang Therapeutics, Inc.
Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors
Regor Pharmaceuticals Inc.
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
Seagen Inc.
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
Pliant Therapeutics, Inc.
A Clinical Study of the Safety and Effectiveness of an Investigational Cell Therapy Given With and Without an Investigational RNA-based Vaccine in Patients With Organ Tumors
BioNTech SE
A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors
Kivu Bioscience Inc.
Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors
MOMA Therapeutics
A Study of XMT-1660 in Participants With Solid Tumors
Mersana Therapeutics
PRESERVE-009
OncoC4, Inc.
ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS)
USWM, LLC (dba US WorldMeds)
FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
Fate Therapeutics
A Study of MOv18 IgE in Patients With Solid Tumours That Express Folate Receptor Alpha
Epsilogen Ltd
A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
IDEAYA Biosciences
Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer
Agenus Inc.
Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors
Whitehawk Therapeutics, Inc.
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
SystImmune Inc.
Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
Xencor, Inc.
A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.
Whitehawk Therapeutics, Inc.
A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer
Sutro Biopharma, Inc.
First-in-Human Study of ATX-559, an Oral Inhibitor of DHX9, in Patients With Advanced or Metastatic Solid Tumors, and Molecularly Defined Cancers
Accent Therapeutics
First in Human Study of IMGN151 in Recurrent Gynaecological Cancers
AbbVie
TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers
Tizona Therapeutics, Inc
First in Human Study of TORL-1-23 in Participants With Advanced Cancer
TORL Biotherapeutics, LLC
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
Normunity AccelCo, Inc.
A Study of MGC026 in Participants With Advanced Solid Tumors
MacroGenics
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
SystImmune Inc.
A Study of PHN-010 in Patients With Advanced Solid Tumors
Pheon Therapeutics
SLV-154 Treatment of Metastatic Solid Tumors
Solve Therapeutics
A Study of DM002 in Patients With Advanced Solid Tumors
Doma Biopharmaceutical(Suzhou)Co., Ltd.
A Study of LY4170156 in Participants With Selected Advanced Solid Tumors
Eli Lilly and Company